PubRank

Merry L Lindsey

Author PubWeight™ 82.54‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Macrophage roles following myocardial infarction. Int J Cardiol 2008 2.14
2 Matrix metalloproteinase-28 deletion exacerbates cardiac dysfunction and rupture after myocardial infarction in mice by inhibiting M2 macrophage activation. Circ Res 2012 1.94
3 Multi-analyte profiling reveals matrix metalloproteinase-9 and monocyte chemotactic protein-1 as plasma biomarkers of cardiac aging. Circ Cardiovasc Genet 2011 1.73
4 Transgenic overexpression of matrix metalloproteinase-9 in macrophages attenuates the inflammatory response and improves left ventricular function post-myocardial infarction. J Mol Cell Cardiol 2012 1.69
5 Effects of early and late chronic pressure overload on extracellular matrix remodeling. Hypertens Res 2008 1.47
6 Proteomic analysis identifies in vivo candidate matrix metalloproteinase-9 substrates in the left ventricle post-myocardial infarction. Proteomics 2010 1.42
7 Matrix metalloproteinase-9: Many shades of function in cardiovascular disease. Physiology (Bethesda) 2013 1.41
8 Altered fibroblast function following myocardial infarction. J Mol Cell Cardiol 2005 1.37
9 Extracellular matrix roles during cardiac repair. Life Sci 2010 1.32
10 Extracellular matrix turnover and signaling during cardiac remodeling following MI: causes and consequences. J Mol Cell Cardiol 2009 1.31
11 Matrix metalloproteinase-9 deletion attenuates myocardial fibrosis and diastolic dysfunction in ageing mice. Cardiovasc Res 2012 1.25
12 The history of matrix metalloproteinases: milestones, myths, and misperceptions. Am J Physiol Heart Circ Physiol 2012 1.22
13 Deletion of thioredoxin-interacting protein in mice impairs mitochondrial function but protects the myocardium from ischemia-reperfusion injury. J Clin Invest 2011 1.21
14 Matrix metalloproteinase (MMP)-9: a proximal biomarker for cardiac remodeling and a distal biomarker for inflammation. Pharmacol Ther 2013 1.21
15 Age-related cardiac muscle sarcopenia: Combining experimental and mathematical modeling to identify mechanisms. Exp Gerontol 2007 1.20
16 Long-lived ames dwarf mice are resistant to chemical stressors. J Gerontol A Biol Sci Med Sci 2009 1.18
17 Effects of deletion of the matrix metalloproteinase 9 gene on development of murine thoracic aortic aneurysms. Circulation 2005 1.15
18 CC chemokine receptor 5 deletion impairs macrophage activation and induces adverse remodeling following myocardial infarction. Am J Physiol Heart Circ Physiol 2011 1.13
19 Matrix metalloproteinase-28 deletion amplifies inflammatory and extracellular matrix responses to cardiac aging. Microsc Microanal 2011 1.09
20 Alterations in cultured myocardial fibroblast function following the development of left ventricular failure. J Mol Cell Cardiol 2006 1.08
21 Monoamine oxidase B prompts mitochondrial and cardiac dysfunction in pressure overloaded hearts. Antioxid Redox Signal 2013 1.04
22 The left ventricle proteome differentiates middle-aged and old left ventricles in mice. J Proteome Res 2008 1.04
23 Texas 3-step decellularization protocol: looking at the cardiac extracellular matrix. J Proteomics 2013 1.01
24 Neutrophil roles in left ventricular remodeling following myocardial infarction. Fibrogenesis Tissue Repair 2013 0.99
25 Myofibroblasts and the extracellular matrix network in post-myocardial infarction cardiac remodeling. Pflugers Arch 2014 0.98
26 Reduced BDNF attenuates inflammation and angiogenesis to improve survival and cardiac function following myocardial infarction in mice. Am J Physiol Heart Circ Physiol 2013 0.97
27 Transformative Impact of Proteomics on Cardiovascular Health and Disease: A Scientific Statement From the American Heart Association. Circulation 2015 0.96
28 In vivo matrix metalloproteinase-7 substrates identified in the left ventricle post-myocardial infarction using proteomics. J Proteome Res 2010 0.95
29 Inhibiting metalloproteases with PD 166793 in heart failure: impact on cardiac remodeling and beyond. Cardiovasc Ther 2008 0.94
30 Toll-like receptor (TLR) 2 and TLR4 differentially regulate doxorubicin induced cardiomyopathy in mice. PLoS One 2012 0.94
31 Extracellular matrix and fibroblast communication following myocardial infarction. J Cardiovasc Transl Res 2012 0.93
32 SPARC mediates early extracellular matrix remodeling following myocardial infarction. Am J Physiol Heart Circ Physiol 2011 0.90
33 Mathematical modeling and stability analysis of macrophage activation in left ventricular remodeling post-myocardial infarction. BMC Genomics 2012 0.89
34 Getting to the heart of the matter: age-related changes in diastolic heart function in the longest-lived rodent, the naked mole rat. J Gerontol A Biol Sci Med Sci 2012 0.89
35 Walking the oxidative stress tightrope: a perspective from the naked mole-rat, the longest-living rodent. Curr Pharm Des 2011 0.88
36 Combining experimental and mathematical modeling to reveal mechanisms of macrophage-dependent left ventricular remodeling. BMC Syst Biol 2011 0.88
37 Citrate synthase is a novel in vivo matrix metalloproteinase-9 substrate that regulates mitochondrial function in the postmyocardial infarction left ventricle. Antioxid Redox Signal 2014 0.88
38 Heart failure with preserved ejection fraction: emerging drug strategies. J Cardiovasc Pharmacol 2013 0.87
39 Effects of surface-modified scaffolds on the growth and differentiation of mouse adipose-derived stromal cells. J Tissue Eng Regen Med 2007 0.86
40 Cardiac extracellular proteome profiling and membrane topology analysis using glycoproteomics. Proteomics Clin Appl 2014 0.86
41 Mathematical modeling of left ventricular dimensional changes in mice during aging. BMC Syst Biol 2012 0.85
42 Applications of miRNA technology for atherosclerosis. Curr Atheroscler Rep 2014 0.84
43 Proteomic analysis reveals late exercise effects on cardiac remodeling following myocardial infarction. J Proteomics 2010 0.84
44 Alterations in Pulse Pressure Affect Artery Function. Cell Mol Bioeng 2012 0.84
45 Alterations of pulse pressure stimulate arterial wall matrix remodeling. J Biomech Eng 2009 0.84
46 Translating Koch's postulates to identify matrix metalloproteinase roles in postmyocardial infarction remodeling: cardiac metalloproteinase actions (CarMA) postulates. Circ Res 2014 0.84
47 Matrix metalloproteinases: drug targets for myocardial infarction. Curr Drug Targets 2013 0.84
48 Artery buckling stimulates cell proliferation and NF-κB signaling. Am J Physiol Heart Circ Physiol 2014 0.83
49 Cardiac wound healing post-myocardial infarction: a novel method to target extracellular matrix remodeling in the left ventricle. Methods Mol Biol 2013 0.83
50 Using proteomics to uncover extracellular matrix interactions during cardiac remodeling. Proteomics Clin Appl 2013 0.83
51 Cardiac function of the naked mole-rat: ecophysiological responses to working underground. Am J Physiol Heart Circ Physiol 2013 0.82
52 Bayesian parameter estimation for nonlinear modelling of biological pathways. BMC Syst Biol 2011 0.82
53 ACE inhibitors to block MMP-9 activity: new functions for old inhibitors. J Mol Cell Cardiol 2007 0.82
54 DHA derivatives of fish oil as dietary supplements: a nutrition-based drug discovery approach for therapies to prevent metabolic cardiotoxicity. Expert Opin Drug Discov 2012 0.81
55 Mechanisms to inhibit matrix metalloproteinase activity: where are we in the development of clinically relevant inhibitors? Recent Pat Anticancer Drug Discov 2007 0.81
56 Roles of saturated vs. polyunsaturated fat in heart failure survival: not all fats are created equal. Cardiovasc Res 2011 0.81
57 Using systems biology approaches to understand cardiac inflammation and extracellular matrix remodeling in the setting of myocardial infarction. Wiley Interdiscip Rev Syst Biol Med 2014 0.80
58 Plasma fractionation enriches post-myocardial infarction samples prior to proteomics analysis. Int J Proteomics 2012 0.80
59 Plasma monitoring of the myocardial specific tissue inhibitor of metalloproteinase-4 after alcohol septal ablation in hypertrophic obstructive cardiomyopathy. J Card Fail 2005 0.80
60 Left ventricular remodeling: one small step for the extracellular matrix will translate to a giant leap for the myocardium. Congest Heart Fail 2013 0.80
61 Estrogen effects on MMP-13 and MMP-14 regulation of left ventricular mass in Dahl salt-induced hypertension. Gend Med 2008 0.80
62 Chronic and intermittent hypoxia differentially regulate left ventricular inflammatory and extracellular matrix responses. Hypertens Res 2012 0.80
63 Understanding the role of the extracellular matrix in cardiovascular development and disease: where do we go from here? J Mol Cell Cardiol 2009 0.80
64 A conceptual cellular interaction model of left ventricular remodelling post-MI: dynamic network with exit-entry competition strategy. BMC Syst Biol 2010 0.80
65 A two-for-one bargain: using cilnidipine to treat hypertension and its comorbidities. J Clin Hypertens (Greenwich) 2013 0.79
66 Obese and diabetic KKAy mice show increased mortality but improved cardiac function following myocardial infarction. Cardiovasc Pathol 2013 0.79
67 Proteomic analysis of the left ventricle post-myocardial infarction to identify in vivo candidate matrix metalloproteinase substrates. Methods Mol Biol 2013 0.78
68 Titin phosphorylation: myocardial passive stiffness regulated by the intracellular giant. Circ Res 2009 0.78
69 Fish oil decreases inflammation and reduces cardiac remodeling in rosiglitazone treated aging mice. Pharmacol Res 2010 0.78
70 Is isolated systolic hypertension worse than combined systolic/diastolic hypertension? J Clin Hypertens (Greenwich) 2012 0.78
71 Cardiac assessment in pediatric mice: strain analysis as a diagnostic measurement. Echocardiography 2013 0.78
72 Thrombospondin-1: the good, the bad, and the complicated. Circ Res 2013 0.78
73 HDL-cholesterol levels and cardiovascular risk: acCETPing the context. Eur Heart J 2008 0.78
74 Crosstalk between cytotoxic T-lymphocyte associated antigen-4 and interleukin-12 in cytotoxic T-lymphocyte-mediated myocarditis: adding another link to the chain. Circ Res 2007 0.77
75 Heart rate reduction: an old and novel candidate heart failure therapy. Hypertension 2012 0.77
76 Systems analysis of gene ontology and biological pathways involved in post-myocardial infarction responses. BMC Genomics 2015 0.76
77 Extracellular matrix proteomics in cardiac ischemia/reperfusion: the search is on. Circulation 2012 0.76
78 Tumor necrosis factor-alpha--converting enzyme roles in hypertension-induced hypertrophy: look both ways when crossing the street. Hypertension 2009 0.75
79 Going out on a LIM and cysteine-rich domains 1 limb: a new way to block calcineurin activity. Hypertension 2009 0.75
80 Heavy hitting: Using water to label humans. Proteomics Clin Appl 2014 0.75
81 Women are different: the role of coupling factor 6 in blood pressure regulation. Hypertens Res 2012 0.75
82 AMP activated protein kinase 2 protection during hypertension-induced hypertrophy: a common mediator in the signaling crossroads. Hypertension 2008 0.75
83 Beta-blockade in heart failure: adding SENIORS to the mix. Eur Heart J 2006 0.75
84 Aging modifies the cardiac response to estrogen: a new dimension to hormone replacement therapy. Hypertension 2006 0.75
85 Tipping the extracellular matrix balance during heart failure progression: do we always go right? Cardiology 2010 0.75
86 Clinical and Translational Proteomics Focused on Tissue Damage, Repair, and Regeneration. Proteomics Clin Appl 2016 0.75
87 Elevated serum osteoprotegerin is associated with increased left ventricular mass index and myocardial stiffness. J Cardiovasc Med (Hagerstown) 2017 0.75